Home
Careers
Conferences
Directory
Drug Discovery
Genes
InDepth
Marketing
News
Reports
Videos
Search
Contact
Items Ordered:
Cart Value:
New Products:
1.
Virtual Pharma - the radical route to success
2.
Manufacturing in the Global Pharmaceuticals Industry Key drivers, company strategies and regulations (3rd Edition)
Best Sellers:
1.
BioNewsCast Press Release Distribution Service
2.
Latest Chinese Regulations for Imported Drug Registration A Comprehensive Guidebook for Foreign Pharmaceutical Companies
3.
5th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, March 2008
4.
Microarray Markets
5.
Neuropatic Pain - Three Course Suite
6.
Contract Research Annual Review 2008
7.
Latest Chinese Regulations for Imported Drug Registration
8.
Pharmaceutical Distribution in Europe The Emergence of Direct-to-Pharmacy Supply
Biogenerics, World Market
Worldwide interest in biogenerics or biosimilars is gaining momentum. Since Kalorama Information last visited the market for synthetic or recombinant versions of natural biologic substances, including proteins such as enzymes or antibodies four years ago, there has been much more worldwide involvement in the development of the biogeneric arena.
The biological drug market is at a crossroad. Some of the biggest-selling biological drugs developed during the first phase of the biotechnology revolution in the 1980s, including human growth hormone (hGH) and insulin, have lost patent protection or are set to lose patent protection in the US in 2007 and beyond. This opens up the market currently worth $40 billion and growing at over 20% per year if the regulatory hurdles can be overcome.
Kalorama Information's survey includes as part of its market analysis a breakdown of generic replacements for:
* Drugs with Active patents
* Drugs with Expired patents
with this geographic breakdown:
* World
* US
* non-US
In addition to market information, this report includes:
* Complete Overview
* Patent dates for Major Biopharmaceuticals
* Issues and Trends in the Industry
* Scientific Differences Between Biopharmaceuticals and Biogenerics
* Key Regulations Affecting this Market
* Company Profiles
As part of Kalorama Information's trusted information gathering process, this report is the result of both primary and secondary research. In addition to exhaustive research, Key executives at biogeneric companies were consulted to uncover key trends and develop models.
Apr 1, 2008 153 Pages
Table of Contents
Price
$3,900.00 Hard copy postal mail deliver
$7,000.00 Global Site Licence
$4,300.00 Online download plus 1 hard copy
$3,500.00 Online Download
Buy Biotechnology Management Reports online with BioPortfolio's secure E-Commerce portal.